Matches in Wikidata for { <http://www.wikidata.org/entity/Q37687754> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q37687754 description "article científic" @default.
- Q37687754 description "article scientifique" @default.
- Q37687754 description "articolo scientifico" @default.
- Q37687754 description "artigo científico" @default.
- Q37687754 description "artículu científicu espublizáu en 2010" @default.
- Q37687754 description "bilimsel makale" @default.
- Q37687754 description "scientific article published on 04 February 2010" @default.
- Q37687754 description "vedecký článok" @default.
- Q37687754 description "vetenskaplig artikel" @default.
- Q37687754 description "videnskabelig artikel" @default.
- Q37687754 description "vědecký článek" @default.
- Q37687754 description "wetenschappelijk artikel" @default.
- Q37687754 description "wissenschaftlicher Artikel" @default.
- Q37687754 description "наукова стаття, опублікована в лютому 2010" @default.
- Q37687754 description "научни чланак" @default.
- Q37687754 description "مقالة علمية نشرت في 04 فبراير 2010" @default.
- Q37687754 name "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 name "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 name "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 type Item @default.
- Q37687754 label "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 label "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 label "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 prefLabel "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 prefLabel "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 prefLabel "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 P1433 Q37687754-D8618E7A-99BA-4F9E-9391-4E1AF585826A @default.
- Q37687754 P1476 Q37687754-C6838949-2500-4E5E-9EB1-71B302BC2FD9 @default.
- Q37687754 P2093 Q37687754-027910DD-17FC-4EE3-9C25-0079FE30B86F @default.
- Q37687754 P2093 Q37687754-2EEEC2DB-8699-4EFF-9A8F-B687C2EBFBA6 @default.
- Q37687754 P2093 Q37687754-323D8C46-3841-4F39-838A-A33A37388F14 @default.
- Q37687754 P2093 Q37687754-B90E6576-76A8-4084-BA26-A41462F96F6C @default.
- Q37687754 P304 Q37687754-B72554D7-7CD7-4666-AC0E-57514DB101E8 @default.
- Q37687754 P31 Q37687754-64B851A1-B98B-4E81-99B4-3F46E5BC3F96 @default.
- Q37687754 P31 Q37687754-fc7858c0-732f-4e82-922b-89088eadd80f @default.
- Q37687754 P356 Q37687754-504E8EAB-7AF0-4D76-8114-2204E81E1BBF @default.
- Q37687754 P433 Q37687754-FB9D2E4E-F960-4CBD-9D20-BC7F0E9F53BD @default.
- Q37687754 P478 Q37687754-21461C6C-FB47-4CD7-9D81-53AD54ABA638 @default.
- Q37687754 P577 Q37687754-EA6D9C3C-25D6-42C2-A08E-D6067E11AFF8 @default.
- Q37687754 P698 Q37687754-F8BBA821-319D-4713-8487-0ADFC36E34F7 @default.
- Q37687754 P921 Q37687754-6A1799AE-C9DE-4CD7-877A-B9FCCD952519 @default.
- Q37687754 P356 JPHS.09R13FM @default.
- Q37687754 P698 20134114 @default.
- Q37687754 P1433 Q15766064 @default.
- Q37687754 P1476 "The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially" @default.
- Q37687754 P2093 "Akiyoshi Ohtake" @default.
- Q37687754 P2093 "Keiji Miyata" @default.
- Q37687754 P2093 "Masao Sasamata" @default.
- Q37687754 P2093 "Shuichi Sato" @default.
- Q37687754 P304 "135-141" @default.
- Q37687754 P31 Q13442814 @default.
- Q37687754 P31 Q7318358 @default.
- Q37687754 P356 "10.1254/JPHS.09R13FM" @default.
- Q37687754 P433 "2" @default.
- Q37687754 P478 "112" @default.
- Q37687754 P577 "2010-02-04T00:00:00Z" @default.
- Q37687754 P698 "20134114" @default.
- Q37687754 P921 Q1135939 @default.